# Elegen

> Next-generation cell-free DNA synthesis for genetic medicine and vaccine manufacturing.

## Why it is interesting

Elegen speeds GMP-compliant DNA production for genetic medicine — 8VC joined a16z in its $35M Series B in 2024.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series B (May 2024): $35M led by Triatomic Capital; 8VC and a16z Bio + Health re-upped (Businesswire)
- Source: https://elegenbio.com/news/elegen-raises-35-million-in-series-b-to-accelerate-expansion-into-clinical-manufacturing/

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/8vc

---
Source: https://venturecapitaltracker.com/startup/elegen